Thy Nguyen, MD
Clinical Neurophysiology · Houston, TXNPI 1932351707
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,578 of the $133,182 with a category attached, or 83.8%. 28 manufacturers reported payments, led by UCB, Inc. at 47.9% of the total. 2025 is the largest year on record at $47,995, more than ten times the $768 reported in 2019. Among clinical neurophysiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $446.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$64K
- AstraZeneca$35K
- Argenx US, Inc.$32K
- CSL Behring$413
- Takeda Pharmaceuticals U.S.A., Inc.$337
- Grifols USA, LLC$282
- plus $1K from 22 others
Across 7 payments — averaging $9192.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$62K
- Novartis$3K
What the payments were for
- Consulting fees$6,5055%
- Speaking & faculty fees$111,57884%
- Travel & lodging$8,1066%
- Food & beverage$6,9575%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 94 | $63,848 |
| AstraZeneca(2 entities) | 61 | $35,480 |
| Argenx US, Inc. | 58 | $31,596 |
| CSL Behring | 22 | $413 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $337 |
| Grifols USA, LLC | 13 | $282 |
| Corium, LLC | 4 | $167 |
| Sanofi | 3 | $147 |
| Greenwich Biosciences, Inc. | 2 | $144 |
| Acorda Therapeutics, Inc | 1 | $103 |
| Biogen | 5 | $81 |
| Johnson & Johnson(2 entities) | 3 | $62 |
| AbbVie | 2 | $51 |
| Novartis | 2 | $46 |
| Pfizer | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 3 | $41 |
| Hospira, Inc. | 2 | $41 |
| Eisai Inc. | 1 | $37 |
| Catalyst Pharmaceuticals, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Strongbridge US Inc. | 2 | $33 |
| Amgen | 2 | $26 |
| Advanced Respiratory, Inc | 1 | $26 |
| Adamas Pharmaceuticals, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,182 in reported general payments places this provider in the 95th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 14 | $849,432 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $506,488 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 41 | $430,008 |
| SolirisEculizumab | 17 | $424,797 |
| Radicava OrsEdaravone | 22 | $322,951 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $286,541 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 30 | $10,199 |
| Mycophenolate Mofetil | 102 | $7,916 |
| Riluzole | 21 | $5,224 |
| Pyridostigmine Bromide | 73 | $5,059 |
| Gabapentin | 195 | $2,717 |
| Azathioprine | 30 | $1,101 |
| Duloxetine Hcl | 55 | $1,073 |
| Pregabalin | 82 | $1,071 |
| Carbamazepine ErCarbamazepine | 12 | $992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart | $31,596 | $849,43214 claims |
| Grifols USA, LLCGamunex-C | $282 | $506,48824 claims |
| PfizerOctagam | $44 | $430,00841 claims |
| AstraZenecaSoliris | $35,480 | $424,79717 claims |
| CSL BehringHizentra | $413 | $286,54113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Houston
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Sudha TallavajhulaHouston$14K
- Victor LevinHouston$10K
- Shaun SmartHouston$9K
- Kristin BrownHouston$5K
- Jay GavvalaHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.